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Multimorbidity, physical frailty, and self-
rated health in older patients with atrial
fibrillation
Hawa O. Abu1* , Jane Saczynski2, Jordy Mehawej1, Tenes Paul1, Hamza Awad3, Benita A. Bamgbade2,
Isabelle C. Pierre-Louis2, Mayra Tisminetzky4,5, Catarina I. Kiefe5, Robert J. Goldberg5 and David D. McManus1
Abstract
Background: Holistic care models emphasize management of comorbid conditions to improve patient-reported
outcomes in treatment of atrial fibrillation (AF). We investigated relations between multimorbidity, physical frailty,
and self-rated health (SRH) among older adults with AF.
Methods: Patients (n = 1235) with AF aged 65 years and older were recruited from five medical centers in
Massachusetts and Georgia between 2015 and 2018. Ten previously diagnosed cardiometabolic and 8 non-
cardiometabolic conditions were assessed from medical records. Physical Frailty was assessed with the
Cardiovascular Health Study frailty scale. SRH was categorized as either “excellent/very good”, “good”, and “fair/
poor”. Separate multivariable ordinal logistic models were used to examine the associations between
multimorbidity and SRH, physical frailty and SRH, and multimorbidity and physical frailty.
Results: Overall, 16% of participants rated their health as fair/poor and 14% were frail. Hypertension (90%),
dyslipidemia (80%), and heart failure (37%) were the most prevalent cardiometabolic conditions. Arthritis
(51%), anemia (31%), and cancer (30%), the most common non-cardiometabolic diseases. After multivariable
adjustment, patients with higher multimorbidity were more likely to report poorer health status (Odds Ratio
(OR): 2.15 [95% CI: 1.53–3.03], ≥ 8 vs 1–4; OR: 1.37 [95% CI: 1.02–1.83], 5–7 vs 1–4), as did those with more
prevalent cardiometabolic and non-cardiometabolic conditions. Patients who were pre-frail (OR: 1.73 [95% CI:
1.30–2.30]) or frail (OR: 6.81 [95% CI: 4.34–10.68]) reported poorer health status. Higher multimorbidity was
associated with worse frailty status.
Conclusions: Multimorbidity and physical frailty were common and related to SRH. Our findings suggest that
holistic management approaches may influence SRH among older patients with AF.
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Background
Among patients with atrial fibrillation (AF), considerable
attention has been paid to long-term clinical outcomes,
adherence to, and effectiveness of AF therapy [1, 2]. The
onset of AF is often associated with distressing symp-
toms such as heart palpitations, extreme fatigue, and
shortness of breath [3]. Symptoms and fear of complica-
tions from AF can lead to significant impairment in pa-
tient’s health status, especially in the setting of
multimorbidity and accompanying frailty in older pa-
tients. Since self-rated health (SRH) status is a major tar-
get of therapeutic interventions including catheter and
surgical ablation in many patients with AF [4, 5], under-
standing the factors that are related to SRH are of great
importance.
The incidence of AF increases with advancing age, af-
fecting approximately 1 in 10 adults aged 65 years and
older in the US [6]. Since AF occurs more commonly in
the elderly who have a higher burden of multimorbidity,
the combination of underlying AF and coexisting dis-
eases may lead to increasingly impaired functional status
[7, 8]. Furthermore, there are complex interactions be-
tween a patient’s history of chronic disease and their
overall well-being depending on the type and combin-
ation of conditions, whether the comorbid conditions
interact or have synergistic effects, and the patient’s
frailty status [9].
Frailty, a concept distinct from multimorbidity, is a
multi-dimensional syndrome characterized by height-
ened vulnerability to stressors with accompanying low
physiological reserve in the presence of multiple organ
impairment [10]. Frailty often occurs in the setting of
normal aging and can progress in severity with more
profound disability [10]. There is a lack of consensus in
defining frailty which could range from vulnerability in
physical, nutritive, cognitive, or sensory domains to im-
pairment in one’s gait speed or handgrip strength as in-
dicators of frailty [11]. In the present study, we assess
physical frailty phenotype developed by Fried and col-
leagues based on their work using two large epidemio-
logic studies, the Cardiovascular Health Study and
Women’s Health and Aging Studies [12]. With a greater
proportion of elderly patients seeking care for AF, frailty
should be increasingly considered in clinical decision-
making process as a factor that may affect patient’s
health status.
The World Health Organization recommends the use
of a person’s SRH status as an important indicator of
their overall health, a concept that captures aspects of
one’s biological, physical, social, and mental functioning
[13]. SRH has been linked with a range of health out-
comes including hospitalizations, morbidity, and mortal-
ity in the general population [14, 15] and in different
patient populations [16, 17].
In older patients with AF, there is a need for greater
understanding of how the presence of multimorbidity
and physical frailty may affect their SRH. The objectives
of the present observational study were to describe the
overall SRH status of a large cohort of older men and
women with AF and examine the independent cross-
sectional associations between multimorbidity, physical
frailty, and SRH status. We hypothesized that multimor-
bidity and physical frailty would be prevalent in our
older study population and may be associated with
poorer functional status and SRH.
Methods
Study population
We used baseline data from the prospective multi-center
study entitled “Systematic Assessment of Geriatric Ele-
ments in AF (SAGE-AF)”. Details of participant recruit-
ment and study protocols have been described
previously [18–20]. Participants were recruited from
three medical centers in Massachusetts and two medical
centers in Central Georgia between 2015 and 2018. Eli-
gible participants were patients aged 65 years and older
who had a diagnosis of AF with the presence of arryth-
mia on electrocardiography tracings, a Holter monitor,
or if AF was documented in any clinic or hospital med-
ical record. The Institutional Review Boards at partici-
pating sites approved this study. Written informed
consent was obtained from each eligible participant prior
to formal study enrollment. Data was abstracted from
hospital medical records by trained research personnel.
Additionally, face-to-face or telephone interviews were
conducted with enrolled participants.
Assessment of multimorbidity
Eighteen previously diagnosed chronic comorbid condi-
tions were assessed from participants’ electronic medical
records. These conditions were chosen based on the co-
morbidities identified and recommended for multimor-
bidity research by the US Department of Health and
Human Services (US-DHHS) Strategic Framework on
Multiple Chronic Conditions [21]. Among the US-
DHHS list of 20 conditions, we excluded those condi-
tions with a very low prevalence in our study population
or were not readily available in the medical records in-
cluding autism (n = 0), human immunodeficiency viral
infection (HIV; n = 0), schizophrenia (n = 0), illicit drug
use (n = 11), and liver disease (n = 31). Patients with de-
mentia were not eligible for study enrollment to avoid
undue burden from study interviews. A diagnosis of
osteoporosis was not ascertained from medical records
due to inconsistency/incomplete documentation. For
purposes of understanding the impact of varying chronic
conditions on patients’ SRH status, we classified the 18
conditions as either cardiometabolic or non-
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cardiometabolic. Ten cardiometabolic conditions were
assessed including hypertension, dyslipidemia, diabetes,
heart failure, valvular heart disease, cardiomyopathy,
myocardial infarction, angina, peripheral vascular dis-
ease, and ischemic stroke. The eight non-
cardiometabolic diseases included were arthritis, anemia,
cancer, chronic kidney disease, chronic lung disease, de-
pression, anxiety, and hypothyroidism. Based on the dis-
tribution of these chronic conditions in our study
participants, we created comparison categories for all
types of chronic conditions (1–4, 5–7, ≥8), cardiometa-
bolic (1–2, 3–4, ≥5), and non-cardiometabolic (1–2, 3–4,
≥5) conditions.
Measurement of physical frailty
The Cardiovascular Health Study (CHS) frailty scale was
used to assess the frailty status of study participants,
based on five components including unintentional
weight loss/shrinking, exhaustion/reduced energy levels,
low physical activity, weak grip strength (assessed by a
hand dynamometer/grip strength meter), and slow gait
speed identified by a 15-ft timed walk [12]. Based on the
CHS guidelines, participants with 3 or more of the 5
components were classified as frail, those with 1–2 com-
ponents were categorized as pre-frail, and participants
with none of these components were considered to be
non-frail [12].
Assessment of SRH status
At the time of study enrollment, participant’s SRH status
was evaluated with a validated and reliable single-item
measure with responses on a 5-point Likert scale which
asked: “In general, would you say your health is excel-
lent, very good, good, fair, or poor?” [22]. Due to the
relatively small sample sizes in the extreme categories of
SRH status, namely those who reported their health as
either excellent (n = 95) or poor (n = 14), we categorized
study participants into three groups as either having “ex-
cellent/very good”, “good” or “fair/poor” SRH status
respectively.
Baseline participant characteristics
The sociodemographic factors assessed by in-person or
telephone interviews included the patient’s age, sex,
race/ethnicity, marital status, and highest educational
level attained. Clinical measures retrieved from patient
medical records and in-person interviews included type
of AF, history of AF symptoms in the preceding 4 weeks,
receipt of ablation therapy, anticoagulation therapy (dir-
ectly acting anticoagulants or warfarin), polypharmacy
(defined as ≥5 medications) and calculated risk scores
including the CHA2DS2-VASc for stroke risk (congest-
ive heart failure, hypertension, age, diabetes, prior
stroke/TIA, vascular disease [peripheral arterial disease,
previous MI, aortic atheroma] and sex category) [23],
HASBLED for 1-year risk of major bleeding (hyperten-
sion, abnormal renal and liver function, prior stroke,
prior bleeding, labile INR, elderly, drugs or alcohol that
increase risk of bleeding) [23], and Charlson Comorbid-
ity index [24]. Psychosocial and geriatric elements de-
rived from comprehensive structured interviews
included measures of low social support, cognitive im-
pairment, independent functioning, and self-reports of
hearing and visual impairment. Five items of the Medical
Outcomes Social Support Survey assessing emotional/in-
formational, tangible, affectionate, and positive social
interaction were used to assess social support [25]. The
30-item Montreal Cognitive Assessment Battery (MoCA)
was used in assessing participant cognition [26]. The in-
strumental activities of daily living was utilized in exam-
ining level of independence in the following areas: basic
communication skills, transportation, meal preparation,
shopping, housework, managing medications, and per-
sonal finances [27]. Health behaviors such as smoking
history and alcohol use were directly reported by
participants.
Statistical analysis
We compared differences in participant’s baseline socio-
demographic, clinical, geriatric, and psychosocial charac-
teristics, as well as their health behaviors across the
three categories of SRH status (excellent/very good vs.
good vs. fair/poor). Continuous variables were summa-
rized either as means and standard deviations with nor-
mal distribution patterns, or as medians and
interquartile ranges with skewed distribution pattern.
We used the non-parametric Wilcoxon rank-sum test to
compare continuous variables across the ordered SRH
levels. The Cochran–Armitage test for trend was used
for between group comparisons for categorical variables.
In examining the association between multimorbidity,
physical frailty, and SRH status, ordinal logistic regres-
sion models were used to assess both the crude and
multi-variable adjusted odds ratios (ORs) and accom-
panying 95% confidence intervals (CI). Separate regres-
sion models were constructed to examine the
association between: i) multimorbidity (all comorbid
conditions, cardiometabolic, and non-cardiometabolic)
and SRH (outcome); ii) physical frailty and SRH (out-
come); and iii) multimorbidity and physical frailty (out-
come). Potential confounding variables were selected
based on clinical judgement and factors associated with
multimorbidity, physical frailty, and/or SRH. We system-
atically examined the impact of a number of potentially
confounding variables by sequential adjustment of par-
ticipant characteristics. First, sociodemographic charac-
teristics were included in the model (age, sex, race/
ethnicity, marital status, and highest level of education).
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Subsequently, clinical variables and health behaviors
(symptoms of AF, type of AF, ablation type, alcohol use,
and smoking status) were added to the models. Lastly,
psychosocial and geriatric measures including low social
support, independent functioning, cognitive, hearing,
and visual impairment, were adjusted for in the regres-
sion model. Physical frailty was also adjusted for as a po-
tential confounder in the regression model assessing the
relationship between multimorbidity and SRH, and mul-
timorbidity was adjusted in the model assessing the rela-
tionship between frailty and SRH. The proportional odds
assumption for the ordinal logistic regression models
was sufficiently met when evaluated with the Brant test
[28]. Post-hoc analyses were conducted with pairwise
comparisons using Bonferroni corrections [29] for mul-
tiple testing across the respective multimorbidity cat-
egories. A two-sided p-value less than 0.05 was
considered statistically significant.
Results
Participants without information on their SRH status
(n = 9) were excluded from the present analysis, resulting
in an analytic sample of 1235 patients diagnosed with
AF. The mean age of study participants was 76 years,
49% were women, and 86% were White (Table 1).
Study participant characteristics according to self-rated
health status
Overall, 40% (n = 491) of study participants reported
their perceived health status as excellent/very good, 44%
(n = 540) as good, and 16% (n = 204) as fair/poor. Based
on our trend test analysis, participants who rated their
health status as “fair/poor” were more likely to be non-
White and unmarried, and to have less than a high
school education compared with those who rated their
health as either “excellent/very good” or “good” (Table
1). A significantly higher proportion of those who per-
ceived their health as being “fair/poor” reported experi-
encing AF symptoms in the 4 weeks prior to study
enrollment, had poorer comorbidity and bleeding risk
scores, and were taking 5 or more medications (poly-
pharmacy) than those who ranked their health as “excel-
lent/very good” or “good” (Table 1).
Frequency of previously diagnosed multiple chronic
conditions and frailty
Almost all study participants (99.5%, n = 1229) had at
least one previously diagnosed comorbid condition. The
most prevalent cardiometabolic conditions were hyper-
tension (90%), dyslipidemia (80%), and heart failure
(37%). The most common non-cardiometabolic condi-
tions were arthritis (51%), anemia (31%), and cancer
(30%). Participants who rated their health as fair/poor
tended to have a higher prevalence of the cardiometa-
bolic and non-cardiometabolic conditions (Table 2).
Overall, slightly over one-third of study participants
had 1–4 (n = 441) or 5–7 (n = 460) previously diagnosed
comorbid conditions respectively, while one-quarter
(n = 328) had 8 or more chronic conditions. The distri-
bution of cardiometabolic conditions were as follows: 1–
2 (n = 390), 3–4 (n = 514), ≥5 (n = 309) conditions. The
non-cardiometabolic conditions were distributed as the
following: 1–2 (n = 480), 3–4 (n = 414), and ≥ 5 (n = 210)
conditions (Table 3).
Approximately 14% (n = 170) of study participants
were classified as being frail, slightly more than half as
pre-frail (n = 659), and approximately one-third were
considered to be non-frail (n = 413) (Table 2).
Association between multimorbidity, physical frailty, and
SRH
From the fully adjusted ordinal logistic regression
models, patients were more likely to report poorer SRH,
with increasing number of all comorbidities (OR: 2.15
[95% CI: 1.53–3.03], ≥ 8 vs 1–4; OR: 1.37 [95% CI: 1.02–
1.83], 5–7 vs 1–4), cardiometabolic (OR: 2.21 [95% CI:
1.56–3.14], ≥ 5 vs 1–2; OR: 1.51 [95% CI: 1.12–2.03], 3–
4 vs 1–2), and non-cardiometabolic (OR: 1.54 [95% CI:
1.06–2.22], ≥ 5 vs 1–2) conditions (Table 3). We found
some heterogeneity in the effect estimates from the car-
diometabolic versus non-cardiometabolic regression
models. The odds ratios from the fully adjusted cardio-
metabolic regression models were of higher magnitude
and remained statistically significant for the respective
multimorbidity group comparisons (Table 3). After use
of Bonferroni corrections, we observed statistically sig-
nificant pairwise comparisons for all types of multimor-
bidity (≥8 vs 1–4 and 5–7) and the cardiometabolic (≥5
vs 1–2) conditions (p < 0.01).
In the multivariable ordinal logistic regression model
assessing the relationship between frailty categories and
SRH status, pre-frailty (OR: 1.73 [95% CI: 1.30–2.30])
and frailty (OR: 6.81 [95% CI: 4.34–10.68]) were signifi-
cantly associated with worse SRH status (Table 4).
Participants with a higher burden of all types of co-
morbid conditions were more likely to be frail (OR: 1.65
[1.20–2.28], ≥ 8 vs 1–4) as were those with more preva-
lent cardiometabolic conditions (OR:1.58 [1.12–2.21], ≥
5 versus 1–2) (Table 5).
Discussion
In this contemporary cohort of patients with AF, we ob-
served a high prevalence of cardiometabolic and non-
cardiometabolic multimorbidity. One in six patients per-
ceived their overall health status as being fair/poor.
More than one-half of study participants met the criteria
for being pre-frail, whereas one in seven were classified
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Table 1 Baseline sociodemographic, clinical, geriatric, and psychosocial characteristics of study participants overall and by self-rated
health
Characteristics Overall
Analytic
Sample
(n = 1235)
Excellent/
Very Good
Self-Rated Health
(n = 491)
Good
Self-Rated Health
(n = 540)
Fair/Poor
Self-Rated Health
(n = 204)
P-value for trend
Socio-demographic
Age (mean, yrs. (sd)) 75.5 (7.1) 75.6 (7.1) 75.5 (7.0) 75.0 (7.2) 0.85
Age categories (%)
65–74 years 50.5 50.1 50.6 51.0 0.73
75–84 years 36.4 36.5 36.1 37.2
≥ 85 years 13.1 13.4 13.3 11.8
Women (%) 48.7 45.6 50.4 51.5 0.10
Race/Ethnicity (%)
White 86.3 92.4 86.8 70.1 < 0.001
Non-White 13.7 7.6 13.2 29.9
Married (%) 56.7 62.3 54.4 49.2 < 0.01
Education
≤ high school 37.5 28.2 40.6 52.3 < 0.001
Some college 19.3 17.0 21.4 19.3
College graduate 43.2 54.8 38.0 28.4
Clinical
AF Type (%)
Paroxysmal 66.4 70.6 62.5 66.8 0.18
Persistent 15.1 12.4 16.9 16.6
Permanent 18.5 17.0 20.6 16.6
Ablation Therapy (%) 30.7 28.3 31.8 33.3 0.14
Symptoms of AF in past 4 weeks (%) 29.6 25.9 31.2 34.2 0.02
Anticoagulation therapy (%)
DOAC 37.5 36.5 38.5 37.3 0.30
Warfarin 48.2 46.8 49.1 49.0
None 14.3 16.7 12.4 13.7
Polypharmacy (≥5 medications) (%) 28.4 22.4 28.5 42.6 < 0.001
CHA2DS2-VASc > 2 (%) 89.1 84.1 90.6 97.1 < 0.001
HASBLED ≥3 (%) 74.1 69.6 75.9 79.9 < 0.01
Charlson comorbidity index, (mean, SD) 6.0 (2.6) 5.5 (2.3) 6.1 (2.5) 7.2 (2.9) < 0.001
Charlson comorbidity index, categories (%)
1–2 4.9 7.9 3.3 2.0 < 0.001
3–4 26.3 31.0 26.1 15.7
≥ 5 68.8 61.1 70.6 82.4
Psychosocial and Geriatric
Low social support (%) 26.6 21.0 28.7 34.3 < 0.001
Cognitive impairment (%) 35.9 29.6 36.7 49.0 < 0.001
Hearing impairment (%) 36.2 33.6 35.2 45.1 0.01
Visual impairment (%) 34.2 17.3 38.3 64.2 < 0.001
Frailty (%)
Not Frail 33.4 47.4 28.7 12.2 < 0.001
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Table 1 Baseline sociodemographic, clinical, geriatric, and psychosocial characteristics of study participants overall and by self-rated
health (Continued)
Characteristics Overall
Analytic
Sample
(n = 1235)
Excellent/
Very Good
Self-Rated Health
(n = 491)
Good
Self-Rated Health
(n = 540)
Fair/Poor
Self-Rated Health
(n = 204)
P-value for trend
Pre-Frail 52.8 49.2 56.7 51.0
Frail 13.8 3.3 14.6 36.8
Independent functioning (IADLs) (Mean, SD) 6.7 (0.8) 6.9 (0.6) 6.7 (0.8) 6.5 (1.1) < 0.001
Health behaviors
Alcohol use (%) 54.9 65.8 51.7 37.4 < 0.001
Smoking status (%)
Never smoker 46.7 52.1 43.7 41.6 < 0.01
Former smoker 50.1 45.7 52.9 53.5
Current Smoker 3.2 2.3 3.4 4.9
Abbreviations: DOAC Direct Oral Anticoagulant, CHA2DS2-VASc Stroke risk assessment (Congestive heart failure, Hypertension, Age (≥ 65 = 1 point, ≥ 75 = 2 points),
Diabetes, and prior Stroke/TIA (2 points), Vascular disease (peripheral arterial disease, previous MI, aortic atheroma) and female gender); HASBLED: Determines 1-
year risk of major bleeding (Hypertension, Abnormal renal and liver function, prior Stroke, prior Bleeding, Labile INR, Elderly, Drugs or alcohol that increase risk of
bleeding); IADLs: Instrumental Activities of Daily Living (score ranging from 0 to 7)
Table 2 Prevalence of previously diagnosed conditions, overall and by self-rated health status: SAGE-AF, 2015–2018 (n = 1235)
Comorbidities Overall Prevalence
n (%)
Excellent/Very Good
Self-Rated Health
(n = 491)
Good
Self-Rated
Health
(n = 540)
Fair/Poor
Self-Rated
Health
(n = 204)
P-value for trend
Cardiometabolic (n = 10), %
Hypertension 1113 (90.1) 87.0 90.5 96.6 < 0.001
Dyslipidemia 988 (80.0) 78.6 80.2 82.8 0.21
Congestive heart failure 459 (37.2) 23.6 41.8 57.3 < 0.001
Diabetes mellitus 384 (31.1) 20.2 31.5 56.4 < 0.001
Valvular heart disease 306 (24.8) 24.0 24.8 26.5 0.51
Cardiomyopathy 268 (21.7) 16.1 22.2 33.8 < 0.001
Myocardial infarction 241 (19.5) 16.9 17.8 30.4 < 0.001
Angina 195 (15.8) 13.0 15.2 24.0 < 0.01
Peripheral vascular disease 177 (14.3) 12.4 14.6 18.1 0.05
Ischemic stroke 121 (9.8) 8.1 10.0 13.2 0.04
Non-Cardiometabolic (n = 8), %
Arthritis 628 (50.8) 45.4 53.0 58.3 < 0.01
Anemia 388 (31.4) 25.2 31.7 45.6 < 0.001
Cancer 377 (30.5) 31.4 30.6 28.4 0.47
Chronic kidney disease 352 (28.5) 22.0 28.9 43.1 < 0.001
Chronic lung disease 314 (25.4) 17.3 25.9 43.6 < 0.001
Depression 296 (24.0) 17.5 26.8 31.9 < 0.001
Anxiety 287 (23.2) 21.4 24.4 24.5 0.27
Hypothyroidism 272 (22.0) 20.8 22.0 25.0 0.24
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as being frail. In the fully adjusted regression models, we
showed that multimorbidity was strongly associated with
worse SRH status and physical frailty; and participants
who were pre-frail or frail were more likely to report
fair/poor SRH status.
Prevalence of cardiometabolic and non-cardiometabolic
conditions
Consistent with reports from prior studies among pa-
tients with AF [8, 30, 31], hypertension, dyslipidemia,
and congestive heart failure were the most prevalent car-
diometabolic comorbidities diagnosed in our study par-
ticipants. The pathophysiologic basis and clinical
interactions between AF and coexisting cardiometabolic
conditions are well established in the literature [32, 33],
however, living and coping with the burden of these dis-
eases especially with regards to their synergistic effect on
one’s overall well-being and functionality, may be of ut-
most concern to patients and their caregivers.
Overall, non-cardiometabolic conditions had a lower
prevalence compared with the cardiometabolic diseases.
Very few studies have examined the prevalence of non-
cardiometabolic comorbidities in older patients with AF
[34, 35]. In the present study, arthritis (51%), anemia
(31%), and cancer (30%) were most common, which was
inconsistent with the few existing studies that identified
renal failure (10–22%) and chronic lung disease (10–
26%) as more commonly occurring non-cardiometabolic
conditions in these patients [34, 35]. A potential reason
for the lack of consistency across studies in the
Table 3 “Fair/Poor” vs. “Good” or “Very Good/Excellent” Self-Rated Health with multimorbidity category as an independent variable
Multimorbidity Categories Prevalence
n (%)
Unadjusted
OR (95% CI)
Model 1
OR (95% CI)
Model 2
OR (95% CI)
Model 3
OR (95% CI)
All Multimorbidity
*0 6 (0.5)
1–4 441 (35.7) Ref Ref Ref Ref
5–7 460 (37.2) 1.60 (1.24–2.05) 1.50 (1.16–1.94) 1.51 (1.11–2.05) 1.37 (1.02–1.83)
8 or more 328 (26.6) 4.12 (3.11–5.47) 3.26 (2.43–4.37) 3.24 (2.29–4.59) 2.15 (1.53–3.03)
Cardiometabolic
*0 22 (1.8)
1–2 390 (31.6) Ref Ref Ref Ref
3–4 514 (41.6) 1.77 (1.37–2.27) 1.61 (1.24–2.09) 1.72 (1.30–2.29) 1.51 (1.12–2.03)
5 or more 309 (25.0) 3.48 (2.60–4.66) 2.91 (2.15–3.95) 2.74 (1.97–3.82) 2.21 (1.56–3.14)
Non-Cardiometabolic
*0 131 (10.6)
1–2 480 (38.9) Ref Ref Ref Ref
3–4 414 (33.5) 1.74 (1.35–2.23) 1.55 (1.20–2.00) 1.50 (1.14–1.98) 1.33 (0.99–1.77)
5 or more 210 (17.0) 2.99 (2.19–4.09) 2.47 (1.60–3.21) 2.33 (1.64–3.29) 1.54 (1.06–2.22)
*Participants with 0 comorbidities are not included in the regression models
ORs and 95% Confidence intervals were obtained from ordinal logistic regression models
Model 1: Adjusted for sociodemographic variables: age, sex, race, marital status, and highest level of education
Model 2: Adjusted for variables in model 1, clinical variables (symptoms of AF, type of AF, ablation type) and health behaviors (alcohol use and smoking status)
Model 3: Adjusted for variables in model 2 and psychosocial/geriatric measures (low social support, independent functioning, cognitive impairment, hearing
impairment, visual impairment, and frailty status)
Table 4 “Fair/Poor” vs. “Good” or “Very Good/Excellent” Self-Rated Health status with physical frailty status as an independent
variable
Frailty Status Prevalence
n (%)
Unadjusted
OR (95% CI)
Model 1
OR (95% CI)
Model 2
OR (95% CI)
Model 3
OR (95% CI)
Not Frail 413 (33.4) Ref Ref Ref Ref
Pre-Frail 652 (52.8) 2.31 (1.81–2.94) 2.17 (1.68–2.80) 1.87 (1.41–2.47) 1.73 (1.30–2.30)
Frail 170 (13.8) 10.75 (7.47–15.46) 9.44 (6.42–13.89) 7.42 (4.81–11.45) 6.81 (4.34–10.68)
ORs and 95% Confidence intervals were obtained from ordinal logistic regression models
Model 1: Adjusted for sociodemographic variables: age, sex, race, marital status, highest level of education
Model 2: Adjusted for variables in model 1, clinical variables (symptoms of AF, type of AF, ablation type, and multimorbidity) and health behaviors (alcohol use
and smoking status)
Model 3: Adjusted for variables in model 2 and psychosocial/geriatric measures (low social support, independent functioning, cognitive impairment, hearing
impairment, and visual impairment)
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prevalence of non-cardiometabolic comorbidities may be
due to the variability in selected conditions, and whether
these conditions are self-reported or obtained from med-
ical records [36]. There is currently no consensus or
internationally accepted standard on how the co-
occurrence of diseases should be ascertained [37, 38].
Since cardiometabolic conditions occur more frequently
in patients with underlying cardiovascular disease [8, 30,
31], it is more likely that they are similar across studies.
However, there needs to be a more standardized ap-
proach to assessing both cardiometabolic and non-
cardiometabolic comorbid conditions to ensure better
reliability and consistency across studies. Furthermore,
in the context of more integrated approaches to AF
management that emphasize the management of accom-
panying comorbidities to improve AF-related outcomes,
healthcare providers should consider integration of in-
formation about the patient’s burden of chronic comor-
bid conditions when considering interventions focused
on SRH status, such as ablation or anti-arrhythmic
medication administration [4, 5].
Prevalence of physical frailty
Overall, 14% of our study participants met the criteria of
being frail while slightly over one-half were considered
to be pre-frail, which is in keeping with prior reports
from studies among elderly patients with AF in the out-
patient setting [39, 40]. In contrast, prior research
among hospitalized elderly patients with AF has shown a
greater prevalence of frailty ranging from 35 to 80% [41,
42]. In addition, AF has been identified as a potential
marker of frailty in older adults [43]. In a study among
23,174 hospitalized patients, AF was found to be more
prevalent among older persons and associated with
greater comorbidity, longer in-hospital stay, and worse
metabolic profile, suggesting that AF could be a possible
indicator of frailty in the elderly [43]. Despite the high
burden of multimorbidity among our study participants,
our findings of a higher prevalence of pre-frailty as op-
posed to frailty is consistent with reports that a majority
of older persons with multimorbidity are not phenotyp-
ically frail, whereas most of those with frailty have multi-
morbidity [44], further emphasizing that multimorbidity
and frailty are interrelated but distinct concepts.
Our results have clinical implications in outpatient
management, reinforcing the need for a more holistic
and patient-centered approach to chronic disease man-
agement in those responsible for managing patients with
AF, including primary care, cardiology, and electrophysi-
ology healthcare providers, by incorporating assessments
of frailty among elderly patients, especially among those
with multiple chronic conditions. Currently, there is no
gold standard for assessing physical frailty in clinical
practice [45]. Most tools assess between 1 and 5 do-
mains of the components of frailty: weight loss/shrink-
ing, exhaustion, low physical activity, weak grip strength,
Table 5 “Frail” vs. “Pre-Frail” or “Not Frail” status with multimorbidity category as an independent variable
Multimorbidity Categories Prevalence
n (%)
Unadjusted
OR (95% CI)
Model 1
OR (95% CI)
Model 2
OR (95% CI)
Model 3
OR (95% CI)
All Multimorbidity
*0 6 (0.5)
1–4 441 (35.7) Ref Ref Ref Ref
5–7 460 (37.2) 1.48 (1.14–1.91) 1.36 (1.04–1.77) 1.43 (1.08–1.91) 1.38 (1.03–1.83)
8 or more 328 (26.6) 1.99 (1.51–2.62) 1.60 (1.20–2.13) 1.72 (1.25–2.37) 1.65 (1.20–2.28)
Cardiometabolic
*0 22 (1.8)
1–2 390 (31.6) Ref Ref Ref Ref
3–4 514 (41.6) 1.68 (1.30–2.17) 1.46 (1.12–1.91) 1.38 (1.03–1.84) 1.32 (0.99–1.77)
5 or more 309 (25.0) 2.09 (1.57–2.79) 1.68 (1.24–2.28) 1.66 (1.19–2.31) 1.58 (1.12–2.21)
Non-Cardiometabolic
*0 131 (10.6)
1–2 480 (38.9) Ref Ref Ref Ref
3–4 414 (33.5) 1.26 (0.98–1.63) 1.16 (0.89–1.52) 1.28 (0.96–1.70) 1.25 (0.94–1.66)
5 or more 210 (17.0) 1.41 (1.04–1.91) 1.26 (0.92–1.73) 1.34 (0.95–1.89) 1.28 (0.90–1.81)
*Participants with 0 comorbidities are not included in the regression models
ORs and 95% Confidence intervals were obtained from ordinal logistic regression models
Model 1: Adjusted for sociodemographic variables: age, sex, race, marital status, highest level of education
Model 2: Adjusted for variables in model 1, clinical variables (symptoms of AF, type of AF, ablation type) and health behaviors (alcohol use and smoking status)
Model 3: Adjusted for variables in model 2 and psychosocial/geriatric measures (low social support, independent functioning, cognitive impairment, hearing
impairment, and visual impairment)
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and slow gait speed [12]. Multidimensional measures of
frailty that incorporate all 5 domains may not be easy to
utilize in the clinic setting given time constraints and
competing demands of busy clinic encounters [46].
Hence, a more simplified and validated method that ad-
equately captures the key components of physical frailty,
such as the short physical performance battery, may be
more ideal for use in the clinic setting [47]. Routine
frailty assessment during clinical encounters may help
identify patients who are pre-frail and have a greater
predisposition to declining health status. This provides
an opportunity to institute timely interventions targeting
psychosocial or geriatric elements such as social isola-
tion, unexplained weight loss, and reduced mobility,
while optimally managing other coexisting diseases.
Participant perception of their overall well-being
A person’s unique experience and perception of their
overall wellbeing can be adequately captured by SRH
which also reflects one’s ability to thrive in their current
environment [48, 49]. We found that participants who
perceived their health as fair/poor were more likely to
belong to ethnic minority groups, had low social support
networks, were less educated, and reported lower in-
come in comparison with those who ranked their health
as either “excellent/very good” or “good”. Our results
emphasize that one’s social environment and support
networks influences how they perceive their well-being
[49, 50]. In addition, patients who reported experiencing
symptoms of AF in the 4 weeks prior to study enroll-
ment, had poorer stroke and bleeding risk scores, and
were taking 5 or more medications, were more likely to
perceive their overall health status as being fair/poor.
These findings suggest the need for healthcare providers
to be increasingly aware of patients’ individual needs
and the perception of their well-being, since this may
very much influence their illness experience and
recovery.
Association between multimorbidity, physical frailty and
SRH
The strong dose-response relationship that we observed
between SRH, multimorbidity, and physical frailty may
be based on bidirectional mechanisms rather than uni-
directional causal pathways, with the presence of one
fostering the development of the other. For example, in
the presence of multiple chronic illnesses, an individual
who perceives their overall health status as being fair/
poor may have decreased resilience, less optimism re-
garding their health, and a dysfunctional internal regula-
tory mechanism, leading to an increased susceptibility to
the onset of more chronic diseases and frailty [51]. In-
deed, in a recent systematic review, optimism and resili-
ence were linked with a reduced risk of cardiovascular
disease and all-cause mortality [52]. Internal coping
mechanisms have been shown to be linked with better
cardiovascular health which may in turn reduce the bur-
den of multimorbidity [53].
Furthermore, we observed that cardiometabolic condi-
tions had stronger associations with poorer perception
of one’s overall health status, and frailty. A possible rea-
son for this stronger relationship may be that with more
frequent follow-up visits for their underlying cardiovas-
cular disease, patients may be increasingly more aware
of their coexisting cardiometabolic diseases, and this
heightened awareness may overwhelmingly impact their
general functional status and quality of life. Measures
that directly assess how individual comorbid conditions
could impact patients’ quality of life may provide a bet-
ter understanding of the impact of each coexisting dis-
ease on patients’ overall their well-being [54]. In a recent
study among elderly adults with AF, cardiometabolic
multimorbidity was associated with worse clinical out-
comes including a greater risk of stroke, severe bleed-
ing, and heart failure [55]. Future longitudinal studies
should explore potential mechanisms by which multi-
morbidity, physical frailty, and SRH may be interre-
lated and their impact on important clinical
outcomes, to ensure a more holistic approach in the
delivery of patient-centered care.
Study strengths and limitations
Our study has several important strengths. First, we uti-
lized contemporary data from a multi-center cohort of
older men and women managed for AF with detailed
clinical, psychosocial, and geriatric characteristics. Sec-
ond, the measures of physical frailty and SRH employed
in this study are well established and widely accepted
measures, enhancing the validity and reproducibility of
our results. In addition, we ascertained the chronic co-
morbid conditions from medical records which reduces
the likelihood of misclassification bias with over or
underestimation from patient self-reports. Our study
findings should be interpreted in light of certain limita-
tions, however. Given our cross-sectional study design,
we were unable to establish temporality and causality be-
tween multimorbidity, physical frailty, and SRH. Further-
more, the comorbid conditions included in the present
study are inexhaustive as other important age-related
conditions such as sarcopenia (progressive loss of skel-
etal muscle mass and strength) which may impact phys-
ical frailty [56] were not assessed. Also, our findings
have limited generalizability to ethnic minority groups
since most of our study participants were White, and
culture plays an important role in people’s perception of
their well-being. Future studies should be conducted in
more ethnically diverse patient populations with AF.
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Conclusions
Cardiometabolic and non-cardiometabolic comorbid
conditions occur very commonly among patients with
AF. The presence of multimorbidity and physical frailty
was associated with one’s perception of their overall
well-being, with a stronger association observed with in-
creasing number of cardiometabolic conditions and
frailty. Our findings suggest that cardiometabolic condi-
tions may exert a more significant effect on SRH than
non-cardiometabolic conditions in patients with AF.
These findings have important implications in this con-
temporary era focusing on a more holistic approach to
the management of comorbidities among patients with
various coexisting chronic conditions, further emphasiz-
ing the need to take into consideration patients’ percep-
tion of their well-being when making therapeutic
decisions especially in the setting of multimorbidity and/
or physical frailty.
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